News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Keros Therapeutics, Inc. - common stock
(NQ:
KROS
)
16.53
+0.01 (+0.06%)
Streaming Delayed Price
Updated: 10:24 AM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Keros Therapeutics, Inc. - common stock
< Previous
1
2
3
Next >
Keros Therapeutics Inc (NASDAQ:KROS) Emerges as a High-Growth Momentum Breakout Candidate
↗
December 25, 2025
Keros Therapeutics exemplifies a high-growth momentum strategy, combining explosive revenue growth, perfect technical ratings, and a defined breakout setup for potential entry.
Via
Chartmill
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
↗
June 10, 2025
BofA's Zemansky downgraded Keros to Neutral, citing limited near-term upside, cautious sentiment, and unresolved investor concerns.
Via
Benzinga
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
↗
May 29, 2025
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Via
Benzinga
Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price
↗
April 11, 2025
Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp. are all itching for a deal.
Via
Benzinga
Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan
↗
April 10, 2025
Keros Therapeutics launches strategic review and adopts rights plan after investor activity signals potential changes in company control.
Via
Benzinga
Analyst Expectations For Keros Therapeutics's Future
↗
February 27, 2025
Via
Benzinga
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings)
↗
January 17, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
April 10, 2025
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
↗
April 10, 2025
The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control...
Via
Stocktwits
Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump
↗
April 10, 2025
Via
Benzinga
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
↗
April 10, 2025
Via
Benzinga
Where Keros Therapeutics Stands With Analysts
↗
December 16, 2024
Via
Benzinga
Keros Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
↗
November 22, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 10, 2025
Via
Benzinga
Forecasting The Future: 7 Analyst Projections For Keros Therapeutics
↗
April 01, 2025
Via
Benzinga
Crude Oil Rises Sharply; JPMorgan Chase Earnings Top Views
↗
January 15, 2025
Via
Benzinga
Nasdaq Surges Over 2%; Goldman Sachs Posts Upbeat Q4 Results
↗
January 15, 2025
Via
Benzinga
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes
↗
January 15, 2025
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.
Via
Stocktwits
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Dow Tumbles 200 Points; Liquidity Services Shares Spike Higher
↗
December 12, 2024
Via
Benzinga
Topics
Stocks
Gold Falls Sharply; Adobe Shares Dip After Weak Revenue Outlook
↗
December 12, 2024
Via
Benzinga
Nasdaq Down 50 Points; US Initial Jobless Claims Rise
↗
December 12, 2024
Via
Benzinga
Keros Therapeutics Loses 75% Value In A Single Session - Here's Why
↗
December 12, 2024
Keros Therapeutics halts high-dose cibotercept treatment in the TROPOS trial after safety concerns, with topline results anticipated in Q2 2025.
Via
Benzinga
Keros Therapeutics Plummets 73% On Unexpected Side Effects In Hypertension Study
↗
December 12, 2024
The company is continuing to test the lowest dose of its pulmonary arterial hypertension drug.
Via
Investor's Business Daily
Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
December 12, 2024
Via
Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
↗
December 03, 2024
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes.
Via
Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
↗
September 05, 2024
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.
Via
Investor's Business Daily
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
↗
September 03, 2024
Via
Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
September 03, 2024
Via
Benzinga
KROS Stock Earnings: Keros Therapeutics Misses EPS for Q2 2024
↗
August 07, 2024
KROS stock results show that Keros Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
